Dulaglutide non inferior to Victoza for Type 2 Diabetes - Eli Lilly
Eli Lilly and Company announced positive top-line results of the sixth AWARD (Assessment of Weekly AdministRation of LY2189265 in Diabetes) trial for once-weekly dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a treatment for Type 2 Diabetes. In the AWARD-6 study, once-weekly dulaglutide 1.5 mg achieved the primary endpoint of non-inferiority to once-daily Victoxa (liraglutide 1.8 mg from Novo Nordisk, as measured by the reduction of hemoglobin A1c (HbA1c) from baseline at 26 weeks.
Dulaglutide showed itself equal to Victoza and with a more convenient weekly dosing schedule could take market share away from Victoza.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins